Fontconfig warning: ignoring C.UTF-8: not a valid language tag
Lurasidone /lɜːr.ˈræ.sɪ.doʊn/ (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma[2] and marketed by Sunovion in the USA. It has been approved for treatment of schizophrenia by the FDA since 2010. In the USA since 2013, it is also approved for the treatment of depressive episodes associated with bipolar I disorder as well as bipolar II disorder in adults when used alone or in combination with lithium, valproate, or lamotrigine.
